.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Merck
Novartis
Mallinckrodt
Medtronic
Accenture
Citi
US Department of Justice
Baxter
Fuji

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,731,296

« Back to Dashboard

Summary for Patent: 5,731,296

Title: Selective vasodilation by continuous adenosine infusion
Abstract:This invention is concerned with the use of adenosine as an agent for the treatment of human beings. More particularly, this invention is concerned with the administration of adenosine to human patients by continuous intravenous infusion for, inter alia, control of blood pressure, use as a selective vasodilator, decreasing pulmonary vascular resistance, treating acute pulmonary hypertension in conjunction with idiopathic respiratory distress syndrome, in diagnosing pulmonary hypertension in conjunction with cardiac septum defects, in percutaneous transluminal angioplasty (PTCA), in coronary thrombolysis (CTL) and in radionucleide scintography.
Inventor(s): Sollevi; Alf (Bromma, SE)
Assignee: Item Development AB (Stocksund, SE)
Application Number:08/031,666
Patent Claim Types:
see list of patent claims
Use;

No matches for this query

International Patent Family for Patent: 5,731,296

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark253187► Subscribe
Australia613304► Subscribe
Canada1301652► Subscribe
Germany3586993► Subscribe
Germany3588205► Subscribe
Germany3590855► Subscribe
Germany19975044► Subscribe
European Patent Office0275249► Subscribe
Australia5065585► Subscribe
Austria176154► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Accenture
Deloitte
US Army
Dow
Julphar
AstraZeneca
UBS
Johnson and Johnson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot